Published in PLoS Pathog on May 13, 2010
Global epidemiology of HIV infection in men who have sex with men. Lancet (2012) 9.18
Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol (2010) 2.39
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A (2011) 1.93
Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS (2011) 1.88
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology (2013) 1.55
HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis. PLoS Med (2013) 1.55
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (2011) 1.55
HIV transmission. Cold Spring Harb Perspect Med (2012) 1.52
Simple epidemiological dynamics explain phylogenetic clustering of HIV from patients with recent infection. PLoS Comput Biol (2012) 1.51
Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One (2011) 1.46
Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol (2011) 1.44
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol (2012) 1.44
New insights into the evolutionary rate of HIV-1 at the within-host and epidemiological levels. Proc Biol Sci (2012) 1.43
Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol (2011) 1.41
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS Pathog (2017) 1.38
Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med (2011) 1.36
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog (2012) 1.26
Association of HIV diversity and survival in HIV-infected Ugandan infants. PLoS One (2011) 1.23
Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol (2013) 1.18
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
Animal models for microbicide studies. Curr HIV Res (2012) 1.17
Transmission of single and multiple viral variants in primary HIV-1 subtype C infection. PLoS One (2011) 1.16
Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol (2013) 1.16
Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med (2011) 1.14
Barriers to mucosal transmission of immunodeficiency viruses. Blood (2011) 1.14
SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. AIDS Res Hum Retroviruses (2011) 1.13
Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol (2012) 1.13
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol (2012) 1.13
Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol (2011) 1.12
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog (2015) 1.11
Molecular tools for studying HIV transmission in sexual networks. Curr Opin HIV AIDS (2014) 1.10
Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat Rev Microbiol (2015) 1.08
Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology (2016) 1.07
Clinical significance of HIV-1 coreceptor usage. J Transl Med (2011) 1.07
Mucosal simian immunodeficiency virus transmission in African green monkeys: susceptibility to infection is proportional to target cell availability at mucosal sites. J Virol (2012) 1.04
Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol (2013) 1.04
Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS Pathog (2015) 1.04
Viral determinants of HIV-1 macrophage tropism. Viruses (2011) 1.03
Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J Virol (2012) 1.02
Mechanisms and factors that influence high frequency retroviral recombination. Viruses (2011) 1.02
A strong case for viral genetic factors in HIV virulence. Viruses (2011) 1.01
Genetic identity and biological phenotype of a transmitted/founder virus representative of nonpathogenic simian immunodeficiency virus infection in African green monkeys. J Virol (2010) 1.01
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. J Infect Dis (2012) 0.99
Tracking the luminal exposure and lymphatic drainage pathways of intravaginal and intrarectal inocula used in nonhuman primate models of HIV transmission. PLoS One (2014) 0.97
Antigenic properties of the HIV envelope on virions in solution. J Virol (2013) 0.97
HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm. J Clin Microbiol (2013) 0.95
Molecularly tagged simian immunodeficiency virus SIVmac239 synthetic swarm for tracking independent infection events. J Virol (2014) 0.94
Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis. Retrovirology (2012) 0.93
Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One (2011) 0.93
The HIV-1 env protein: a coat of many colors. Curr HIV/AIDS Rep (2012) 0.93
HIV-1 Vpu Mediates HLA-C Downregulation. Cell Host Microbe (2016) 0.93
Stromal down-regulation of macrophage CD4/CCR5 expression and NF-κB activation mediates HIV-1 non-permissiveness in intestinal macrophages. PLoS Pathog (2011) 0.92
Implications of HIV PrEP trials results. AIDS Res Hum Retroviruses (2010) 0.92
Using nonhuman primates to model HIV transmission. Curr Opin HIV AIDS (2013) 0.91
Human immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time. J Infect Dis (2013) 0.91
Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathog (2016) 0.90
Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants. Retrovirology (2011) 0.89
Immune-mediated attenuation of HIV-1. Future Virol (2011) 0.89
HIV-1 target cells in the CNS. J Neurovirol (2014) 0.89
Rectal microbicide development. Curr Top Microbiol Immunol (2014) 0.87
Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B. J Acquir Immune Defic Syndr (2013) 0.86
Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet (2014) 0.86
Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. Future Virol (2010) 0.86
Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. J Virol (2015) 0.86
The intra-host evolutionary and population dynamics of human immunodeficiency virus type 1: a phylogenetic perspective. Infect Dis Rep (2013) 0.86
Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N. J Virol (2012) 0.86
Differential innate immune responses to low or high dose oral SIV challenge in Rhesus macaques. Curr HIV Res (2011) 0.85
Proteomic analysis of HIV-infected macrophages. J Neuroimmune Pharmacol (2010) 0.85
High-accuracy identification of incident HIV-1 infections using a sequence clustering based diversity measure. PLoS One (2014) 0.84
Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. Proc Natl Acad Sci U S A (2017) 0.84
Molecular mechanisms of HIV type 1 prophylaxis failure revealed by single-genome sequencing. J Infect Dis (2013) 0.84
Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus. J Virol (2012) 0.84
Semen CD4+ T cells and macrophages are productively infected at all stages of SIV infection in macaques. PLoS Pathog (2013) 0.84
A Bayesian approach to analyse genetic variation within RNA viral populations. PLoS Comput Biol (2011) 0.84
Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. Open Forum Infect Dis (2014) 0.84
Sexually-transmitted/founder HIV-1 cannot be directly predicted from plasma or PBMC-derived viral quasispecies in the transmitting partner. PLoS One (2013) 0.83
Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4. MBio (2015) 0.83
The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context? Retrovirology (2013) 0.82
Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. Nat Commun (2015) 0.82
For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection. J Virol (2011) 0.82
Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. Retrovirology (2014) 0.82
Proliferation of latently infected CD4(+) T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. J Exp Med (2017) 0.81
Identification and characterization of a macrophage-tropic SIV envelope glycoprotein variant in blood from early infection in SIVmac251-infected macaques. Virology (2014) 0.81
Generation and characterization of a SIVmac239 clone corrected at four suboptimal nucleotides. Retrovirology (2015) 0.81
Human Th17 Cells Lack HIV-Inhibitory RNases and Are Highly Permissive to Productive HIV Infection. J Virol (2016) 0.81
DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics (2003) 32.63
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Statistical properties of the number of recombination events in the history of a sample of DNA sequences. Genetics (1985) 20.92
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature (2005) 11.12
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science (1992) 7.44
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis (2009) 6.96
Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity (2007) 6.36
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol (2005) 5.92
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Glycerol monolaurate prevents mucosal SIV transmission. Nature (2009) 5.02
GARD: a genetic algorithm for recombination detection. Bioinformatics (2006) 4.88
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology (1992) 4.70
Gender differences in HIV-1 diversity at time of infection. Nat Med (2000) 4.69
Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol (2005) 4.61
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40
Recombination: Multiply infected spleen cells in HIV patients. Nature (2002) 4.38
Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A (2004) 4.37
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog (2009) 4.04
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (2004) 3.75
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66
Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med (2003) 3.48
Viral dynamics of acute HIV-1 infection. J Exp Med (1999) 3.45
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25
The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis (1994) 3.16
Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol (2006) 3.13
Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol (1995) 2.98
Reduction of HIV concentration during acute infection: independence from a specific immune response. Science (1996) 2.98
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
Pervasive genomic recombination of HIV-1 in vivo. Genetics (2004) 2.79
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science (2009) 2.64
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis (2004) 2.29
Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol (2006) 2.19
HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog (2009) 2.15
Ultradeep pyrosequencing detects complex patterns of CD8+ T-lymphocyte escape in simian immunodeficiency virus-infected macaques. J Virol (2009) 1.76
HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis (2008) 1.70
Recco: recombination analysis using cost optimization. Bioinformatics (2006) 1.68
Cross-border paid plasma donation among injection drug users in two Mexico-U.S. border cities. Int J Drug Policy (2009) 1.45
Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus. PLoS Pathog (2009) 1.45
Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res (2009) 1.30
Virology. Moving forward in HIV vaccine development. Science (2009) 1.11
HIV vaccine trial results--an opening for further research. N Engl J Med (2009) 1.04
Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. Lancet Infect Dis (2008) 0.95
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Syphilis in China: results of a national surveillance programme. Lancet (2007) 5.76
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Population-based study of chlamydial infection in China: a hidden epidemic. JAMA (2003) 5.40
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35